Atezolizumab + Bevacizumab and Chemotherapy in NSCLC Subgroups With EGFR Mutations or Liver or Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
J Thorac Oncol 2021 Oct 06;[EPub Ahead of Print], N Nogami, F Barlesi, MA Socinski, M Reck, CA Thomas, F Cappuzzo, TSK Mok, G Finley, JG Aerts, F Orlandi, D Moro-Sibilot, RM Jotte, D Stroyakovskiy, LC Villaruz, D Rodríguez-Abreu, DW Lim, D Merritt, S Coleman, A Lee, G Shankar, W Yu, I Bara, M NishioFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.